People: Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

2.69USD
9:30am EDT
Change (% chg)

$0.03 (+1.13%)
Prev Close
$2.66
Open
$2.68
Day's High
$2.69
Day's Low
$2.68
Volume
1,508
Avg. Vol
111,604
52-wk High
$4.68
52-wk Low
$2.15

Search Stocks

Summary

Name Age Since Current Position

John Richard

57 2014 Non-Executive Independent Chairman of the Board

Stephen Hill

56 2012 President, Chief Executive Officer, Director

Mauri Hodges

55 2014 Chief Financial Officer, Vice President of Finance and Administration, Treasurer

Patrick Rock

55 2013 Senior Vice President, General Counsel, Secretary

Scott Cullison

38 2013 Vice President - Business Development

Charles Blixt

64 2000 Independent Director

Julia Brown

67 2007 Independent Director

Errol De Souza

61 2004 Independent Director

Biographies

Name Description

John Richard

Mr. John P. Richard is the Non-Executive Independent Chairman of the Board of Targacept, Inc. Mr. Richard is an operating partner at the life science investment firm Phase4 Partners (formerly Nomura Phase4 Ventures), and has served as a non-executive director for Phase4 since March 2011 and as a venture partner since 2008. Since 2005 he has also been a managing director of Georgia Venture Partners, a seed venture capital firm that focuses on the biotechnology industry. In addition, Mr. Richard currently serves and from time to time during at least the past five years has served as a consultant to Phase4 Partners (or its predecessor) and certain of its portfolio companies, and to portfolio companies of Georgia Venture Partners. Mr. Richard is currently a director of the publicly-traded company Biota Pharmaceuticals, Inc. Mr. Richard brings to the Board extensive business development experience, having led that function at three separate life science companies and played a primary role in establishing numerous pharmaceutical alliances. In addition, the breadth of Mr. Richard’s current roles enables him to view issues that we face from a variety of perspectives, including as an executive, investor, director and business development professional.

Stephen Hill

Dr. Stephen A. Hill, M.D. has been appointed as President, Chief Executive Officer, Director of Targacept, Inc., effective December 1, 2012. From May 2012 to November 2012, Dr. Hill served as president and chief executive officer of QUE Oncology, a start-up biotechnology company, and, from March 2011 to December 2011, he served as president and chief executive officer of 21st Century Biodefense, Inc., a biodefense company. From April 2008 until its acquisition in December 2010, he served as president and chief executive officer of Solvay Pharmaceuticals, Inc., a pharmaceutical company. Prior to Solvay, he served as president, chief executive officer and director of ArQule, Inc., a pharmaceutical company, from April 1999 to March 2008. Dr. Hill is a member of the board of directors of the publicly-traded companies Cellectar Biosciences, Inc. (formerly Novelos Therapeutics, Inc.) and Lipocine, Inc.

Mauri Hodges

Ms. Mauri K. Hodges is Chief Financial Officer, Vice President of Finance and Administration, Treasurer of Targacept, Inc. From July 2014 to November 2014, she was our Vice President of Human Resources and served as Vice President, Finance and Corporate Systems and Controller from 2007 to June 2014.

Patrick Rock

Mr. Patrick C. Rock, J.D. is Senior Vice President, General Counsel, Secretary of TARGACEPT, INC., From April 2009 to December 2011, he served as Vice President and General Counsel to 21st Century Biodefense, Inc., a biodefense company. From January 2012 to August 2013, Mr. Rock maintained his own legal practice counseling multinational pharmaceutical and energy industry clients.

Scott Cullison

Mr. Scott N. Cullison is no longer Vice President, Business Development., effective May 31, 2015. He was our Senior Director, Business and Commercial Development from January 2010 to May 2013 and Director, Business and Commercial Development from January 2006 to December 2009.

Charles Blixt

Mr. Charles A. Blixt is an Independent Director of Targacept, Inc., since August 2000. From October 2007 to December 2010, Mr. Blixt was a senior advisor to Jones Day, a law firm. From September 2006 to April 2007, he served as the interim general counsel of Krispy Kreme Doughnuts, Inc., a branded specialty retailer. From August 2004 to August 2006, he was executive vice president, general counsel and assistant secretary of Reynolds American Inc. From June 1999 to August 2006, he held positions of increasing responsibility with R.J. Reynolds Tobacco Holdings, Inc. and, from January 1998 to August 2006, he served as executive vice president and general counsel of R.J. Reynolds Tobacco Company. Mr. Blixt is a member of the board of directors of the publicly-traded company Krispy Kreme Doughnuts, Inc. Within the past five years, he served as a member of the board of directors of the publicly-traded company Swedish Match AB.

Julia Brown

Ms. Julia R. Brown is an Independent Director of Targacept, Inc., since November 2007. She has held a variety of executive positions over her career in the pharmaceutical industry. Ms. Brown served as Executive Vice President of Amylin Pharmaceuticals, Inc. from 2000-2003 and as Advisor to the CEO until 2008. Prior to joining Amylin, she was Executive Vice President of Dura Pharmaceuticals, Inc. Ms. Brown spent over 25 years with Eli Lilly and Company in progressively more senior roles including Vice President of IVAC Corporation and General Manager of its Vital Signs Division and Vice President of Worldwide Marketing for Hybritech. She currently serves on the board of directors of Biodel, Inc. and Cleveland Biolabs, Inc., both publicly-traded, development stage pharmaceutical companies. She is compensation committee chair and a member of the nominating and governance committee of both companies. Ms. Brown previously served on the boards of five other development stage pharmaceutical companies, including the publicly-traded company Labopharm, Inc. (acquired by Paladin Labs Inc.) from 2007 to 2011. She is Chairman of the Corporate Directors Forum and is a member of the National Association of Corporate Directors and Women Corporate Directors. Ms. Brown is a trustee and chair emerita of the University of California San Diego Foundation and is a member of the board of two industry associations.

Errol De Souza

Dr. Errol B. De Souza, Ph.D. is an Independent Director of Targacept, Inc., Since March 2010, Dr. De Souza has been president and chief executive officer of Biodel Inc., a specialty pharmaceutical company. From April 2009 to March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to March 2009, he served as president and chief executive officer of Archemix Corporation, a privately held biopharmaceutical company. Dr. De Souza currently serves as a member of the board of directors of each of the publicly-traded companies Biodel Inc. and Bionomics Ltd. Within the past five years, he served on the board of directors of each of the publicly-traded companies IDEXX Laboratories, Inc. and Palatin Technologies, Inc.

Basic Compensation

Name Fiscal Year Total

John Richard

--

Stephen Hill

1,677,310

Mauri Hodges

537,958

Patrick Rock

648,543

Scott Cullison

482,885

Charles Blixt

--

Julia Brown

--

Errol De Souza

--
As Of  30 Dec 2014

Options Compensation

Search Stocks